small molecule

ALTABAX

RETAPAMULIN

Loss of exclusivityFebruary 2027latest FDA-listed patent expiry
CompanyAlmirallView the full company profile on CliffBio

Drug detail

Brand nameALTABAX
Active ingredientRETAPAMULIN
Strength1%
Dosage formOINTMENT
RouteTOPICAL
ModalitySmall molecule
FDA approvalApril 2007
Marketing statusDISCN

Listed patents

PatentExpiresType
7875630February 2027substance

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ALTABAX patent cliff — loss of exclusivity February 2027 | CliffBio